<DOC>
	<DOC>NCT00276341</DOC>
	<brief_summary>The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.</brief_summary>
	<brief_title>Study on the Effectiveness of EGb 761® Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Patient with Multiple Sclerosis RelapsingRemitting form Patient with cognitive impairment (as spontaneous complaint by either patient or family) Patient treated with interferon and maintaining same dosage for previous 6 months Patient without major disability (Kurtzke Extended Disability Status Scale ≤6) Clinical Multiple Sclerosis relapse within 3 months prior to participation Major psychiatric disease according to Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Other concomitant disorders possibly jeopardizing the cognitive status evaluation or the follow up of the patient (severe impairment of visual or motor function which may prevent participation in neuropsychological testing)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>cognitive impairment</keyword>
</DOC>